Todays guest is Luise Weigand. Luise joined Zelluna Immunotherapy in January 2021 and serves as Head of Research. Prior to joining Zelluna, Luise was Associate Director Translational Medicine at Autolus, setting up and delivering clinical biomarker analysis for a couple of clinical trials. She was also responsible for leading two projects, which were in early stage clinical trials at cross functional level when joining Autolus. Luise previously spent over 7 years at Immunocore Ltd, where she built and led scientific teams from TCR discovery, through preclinical to early development. Luise received her PhD from the Technical University of Munich/Helmholtz Zentrum Muenchen in cancer immunotherapy in 2011. We discuss topics related to her expertise, if there ever will be a vaccine for cancer, why some people get it and others not, diets role, the demands of such a job and much more! Det beste du kan gjøre for å støtte podcasten er å gi den 5* og trykke "følg" på Spotify eller hvor enn du hører på - takk!😁 Alexander finner du på: Twitter: @AlexBendiksen Facebook: ⁠⁠https://www.facebook.com/profile.php?id=100004906086710⁠⁠ Nettside: www.bendiksenairways.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related